eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
2/2009
vol. 34
 
Share:
Send email
Share:
abstract:

Clinical immunology
CD4+Foxp3+ regulatory T lymphocytes expressing CD62L in patients with long-standing diabetes type 1

Monika Ryba
,
Łukasz Hak
,
Katarzyna Zorena
,
Małgorzata Myśliwiec
,
Jolanta Myśliwska

Centr Eur J Immunol 2009; 34 (2): 90-93
Online publish date: 2009/05/20
View full text Get citation
 
Diabetes type 1 is a chronic autoimmune disease in which insulin-producing cells located in the pancreatic islets of Langerhans are gradually destroyed by autoreactive T cells. Quantitative or qualitative dysfunctions in naturally arising CD4+Foxp3+ T lymphocytes may result in ineffective suppression of autoreactive T cells. CD62L is a surface molecule that plays role in homing capabilities of Tregs in autoimmunity if they must be present in the target tissue in order to have the proper effect. Only cells with high expression of CD62L are able to protect against diabetes. We investigated CD4+Foxp3+ cells expressing CD62L after in vitro stimulation with anti-CD3 from children with long-standing diabetes type 1 and we found lower frequencies of these cells in diabetic group compared to their healthy counterparts.
keywords:

regulatory T cells, diabetes type 1, CD62L, Foxp3
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.